Literature DB >> 3763137

Treatment of facial spasm with botulinum toxin. An interim report.

B R Frueh, D C Musch.   

Abstract

Forty-eight patients were given serial injections of botulinum toxin in their eyelids for treatment of eyelid spasm during a two-year interval. Ninety-four percent obtained relief of spasm from botulinum toxin injection. The duration of the spasm-free interval as well as the incidence of ptosis and of diplopia was dose dependent. The marked increase in the incidence of these side effects with only a small increase in the duration of the spasm-free interval, when a dose of 25 units per lid was used, leads the authors to conclude that this dose is too high and should not be used. Since diplopia was most commonly caused by paresis of the inferior oblique muscle, and since blepharospasm usually can be controlled by excising the upper lid protractors, further studies are required to determine whether lower lid injection is necessary and, if it is found to be so, whether injecting only the lateral portion of the lid would be adequate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3763137     DOI: 10.1016/s0161-6420(86)33641-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

1.  Blepharospasm and Hemifacial Spasm.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-09       Impact factor: 3.598

2.  Low-dose botulinum toxin a for treatment of blepharospasm and hemifacial spasm.

Authors:  Anuchit Poonyathalang; Pisit Preechawat; Uraiwan Jamnansiri
Journal:  Jpn J Ophthalmol       Date:  2005 Jul-Aug       Impact factor: 2.447

3.  Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.

Authors:  A R Bentivoglio; A Fasano; T Ialongo; F Soleti; S Lo Fermo; A Albanese
Journal:  Neurotox Res       Date:  2009-02-24       Impact factor: 3.911

Review 4.  Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases.

Authors:  S Jitpimolmard; S Tiamkao; M Laopaiboon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-06       Impact factor: 10.154

5.  Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years.

Authors:  J A Mauriello; S Dhillon; T Leone; B Pakeman; R Mostafavi; M C Yepez
Journal:  Br J Ophthalmol       Date:  1996-12       Impact factor: 4.638

6.  Botulinum toxin A treatment of overactive corrugator supercilii in thyroid eye disease.

Authors:  J M Olver
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

7.  Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years.

Authors:  J A Mauriello; J Aljian
Journal:  Br J Ophthalmol       Date:  1991-12       Impact factor: 4.638

8.  Outcomes of a regional variant of botulinum toxin type A in the treatment of essential blepharospasm and hemifacial spasms: A retrospective study.

Authors:  V Maneksha; Sabyasachi Chakrabarty; Meghana Tanwar; Madhavi Ramanatha Pillai
Journal:  Indian J Ophthalmol       Date:  2021-10       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.